

## Editorial

## Fibrin opens the “gate” for leukocytes in the endothelium




Migration of blood leukocytes through the layer of endothelial cells into extravascular sites of inflammation is essential for host defense and elimination of the consequences of tissue damage. The transendothelial migration of leukocytes has been shown to be promoted and mediated by various cell adhesion receptors, such as selectins, ICAM-1, and integrins, as well as by multiple chemoattractant molecules [1–4]. Although many aspects of leukocyte transmigration have been studied, some mechanisms, including a link between thrombosis and the recruitment of leukocytes to sites of inflammation, remain not fully elucidated. In this issue of *Thrombosis Research*, an article by Yakovlev and Medved [5] has partially filled this gap by clarifying the molecular basis for the previously discovered novel mechanism of leukocyte transmigration promoted by the interaction of fibrin with the very low density lipoprotein receptor (VLDLR) [6].

The role of fibrin(ogen) and its derivatives in inflammation, including leukocyte transmigration, has been a matter of intensive investigations for decades. Fibrinogen is one of the acute phase proteins up-regulated in response to injury and inflammation, followed by an up to ten-fold increase in its concentration in blood [7]. Both fibrinogen and fibrin are involved in antimicrobial host protection, inflammatory reactions, wound healing, and related pathophysiological processes [8–11]. Despite numerous data that point to a prominent role of fibrin(ogen) in inflammation, the molecular mechanisms of fibrin(ogen)-mediated leukocyte transmigration remain unclear. So far, three main concepts have been put forward to explain the role of fibrin(ogen) in leukocyte transmigration, two of which are based on the physical bridging of leukocytes to the endothelium. First, it was proposed that fibrinogen links leukocytes to the endothelium through its interaction with the leukocyte receptor Mac-1 and endothelial cell receptor ICAM-1, and that such bridging promotes transendothelial migration of leukocytes [12,13]. This mechanism has been questioned because of the fact that soluble fibrinogen is non-reactive with Mac-1, as discussed in the article by Yakovlev and Medved [5]. However, the binding specificity of surface-adsorbed fibrinogen may be distinct from that of its soluble form; therefore, such interaction could not be excluded. Second, it was suggested that fibrin degradation products could bridge leukocytes to the endothelium via their interaction with endothelial VE-cadherin and leukocyte receptor CD11c, also known as the integrin  $\alpha X$  subunit, thus promoting leukocyte transmigration [14]. In particular, the leukocyte migrating activity was attributed to the fibrin degradation product, fragment E<sub>1</sub> [14,15]. However, the E<sub>1</sub> fragment exists only as a part of the D-D:E<sub>1</sub> complex, in which knob ‘A’ (the  $\alpha$ Gly17-Pro18-Arg19 sequence), the active binding site of E<sub>1</sub>, is inaccessible for CD11c, which makes the E<sub>1</sub>-mediated intercellular interaction unlikely, unless some other receptor(s) or portions of E<sub>1</sub> are involved as alternative binding sites. The third mechanism of fibrin(ogen)-mediated leukocyte transmigration proposed earlier by the authors of the present study involves fibrin whose interaction with VLDLR via the N-terminal portions of fibrin  $\beta$  chains, known as  $\beta$ N-domains, promotes leukocyte transmigration [6]. However, there was no direct experimental evidence that fibrin can stimulate leukocyte transmigration via this mechanism. Furthermore, it was unclear which fibrin species, soluble fibrin, fibrin polymers, or fibrin degradation products, are involved in such stimulation. The current article by Yakovlev and Medved [5] addressed these questions.

The authors performed a comprehensive and through study of the interaction of recombinant soluble VLDLR, which is normally expressed in endothelial cells, with fibrinogen, fibrin, and their recombinant fragments corresponding to the fibrin(ogen) (B) $\beta$ N-domains. They also studied the effect of fibrinogen, fibrin, and various fibrin-derived species on transendothelial migration of leukocytes. The authors demonstrated that freshly purified monomeric fibrinogen in solution does not bind to VLDLR and has practically no influence on leukocyte transmigration. However, fibrinogen became highly reactive towards soluble VLDLR either in the adsorbed state or upon conversion to fibrin, implying that the VLDLR-binding site(s) is exposed due to conformational transitions. The study also revealed that the D-D:E<sub>1</sub> complex, high molecular mass fibrin degradation products, soluble fibrin, as well as insoluble fibrin polymers deposited on the endothelium (endothelium-anchored fibrin clots), promote leukocyte transmigration in a VLDLR-dependent manner. These findings provide insights into the molecular and sub-molecular mechanisms underlying the transendothelial migration of leukocytes in thrombotic inflammation and show that it is mediated mainly by the fibrin-VLDLR interaction. Among these findings, the most important one is that endothelium-anchored fibrin clots promote leukocyte transmigration since it establishes an important link between thrombosis and the recruitment of leukocytes to sites of inflammation. This link is demonstrated by a diagram in Fig. 1 providing a summarized mechanistic explanation for the VLDLR-dependent transendothelial migration of leukocytes induced by a fibrin clot deposited on the endothelium, which follows from the article by Yakovlev and Medved [5]. Thus, the results presented in this article certainly have a remarkable (patho)physiological significance because they shed light on clinically and biologically important pathogenic processes underlying many diseases and pathological conditions.

There are a few additional notable points that could be inferred from the article by Yakovlev and Medved [5]. First, this work affirms that a strong mechanistic interplay between inflammation and thrombosis is bidirectional. In other words, it shows that not only local inflammation can enhance hemostatic and thrombotic processes by amplifying clot initiation and limiting fibrinolysis [16], but that fibrin formation and deposition on



**Fig. 1.** Schematic diagram (not to scale) demonstrating a link between intravascular fibrin formation (thrombosis) and the VLDLR-dependent transendothelial migration of leukocytes (inflammation). Thrombin converts monomeric fibrinogen into a fibrin clot, which is deposited on the endothelial surface through the interaction with various endothelial receptors, including the VLDL receptor (VLDLR, shown as the blue bars). The interaction of endothelium-anchored fibrin clots with the VLDL receptor promotes leukocyte (neutrophil) transmigration to the sites of inflammation. Such events may occur in wound healing and other pathological states with local inflammation, for example, in myocardial or brain ischemia-reperfusion injury, which triggers massive leukocyte transmigration to the ischemic tissues, resulting in subsequent tissue damage. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

the endothelium stimulates inflammation by promoting leukocyte recruitment. Second, this work provides a possible mechanistic explanation for the differential role of fibrinogen and fibrin in antimicrobial host defense. In a recent paper by Prasad et al. [10], using a mouse model system that allows the functional distinction between fibrinogen and fibrin, it was shown that mice expressing a mutant form of fibrinogen that cannot support fibrin polymerization exhibit compromised antimicrobial host defense. This means that fibrin, unlike fibrinogen, is critical for antimicrobial mechanisms. The present work by Yakovlev and Medved [5] provides an elegant and plausible explanation for this remarkable observation. Third, it is important that soluble fibrinogen has a cryptic VLDLR-binding site(s) that becomes exposed in adsorbed fibrinogen and in fibrin, which is exactly what we observed in relation to the binding properties of soluble versus surface-attached fibrinogen and fibrin towards the platelet integrin  $\alpha\text{IIb}\beta 3$  [17,18]. To generalize, fibrinogen in solution is different from fibrinogen adsorbed on an interface, which undergoes a conformational transition that makes it similar to fibrin in terms of binding specificity and affinity towards cellular receptors and perhaps other interacting partners. This concept has a remarkable biological importance because adhesive cellular interactions mediated by various protein ligands, including fibrinogen and fibrin, occur entirely at interfaces.

The overall current concept of fibrin-VLDLR-mediated transendothelial leukocyte migration has certainly an imperfection, which is the lack of a complete understanding of the molecular and cellular mechanisms underlying infiltration of leukocytes through the intercellular endothelial space. A priori, migration of blood cells to inflamed extravascular tissue requires activation of both leukocytes and endothelial cells, including formation of a positive feedback loop. It seems plausible that fibrin-VLDLR interaction may result in activation of endothelial cells that not only express adhesion molecules but can also secrete leukocyte-activating and attracting chemical stimuli. It is also possible that fibrin polymers or their soluble fibrin degradation products trigger VLDLR-mediated intracellular signaling that cause structural rearrangements of intercellular junctions that potentially modulate the gaps at the endothelial borders. Alternatively, leukocytes can migrate around endothelial junctions by crossing at tricellular corners [19] and this is another possible target for investigation. These and other potential molecular mechanisms underlying the fibrin-VLDLR-dependent leukocyte trafficking remain to be established.

In summary, the article by Yakovlev and Medved [5] establishes an important mechanistic link between thrombosis and the recruitment of leukocytes to sites of inflammation. In addition to the basic understanding of transendothelial migration of leukocytes, the findings described in this article open up a new avenue for the development of efficient anti-inflammatory therapeutics aimed at new molecular targets.

## References

- [1] W.A. Muller, Mechanisms of leukocyte transendothelial migration, *Annu. Rev. Pathol.* 6 (2011) 323–344.
- [2] S. Nourshargh, R. Alon, Leukocyte migration into inflamed tissues, *Immunity* 41 (2014) 694–707.
- [3] P. Subramanian, I. Mitroulis, G. Hajishengallis, T. Chavakis, Regulation of tissue infiltration by neutrophils: role of integrin  $\alpha 3 \beta 1$  and other factors, *Curr. Opin. Hematol.* 23 (2016) 36–43.
- [4] W.A. Muller, Transendothelial migration: unifying principles from the endothelial perspective, *Immunol. Rev.* 274 (2016) 61–75.
- [5] S. Yakovlev, L. Medved, Effect of fibrinogen, fibrin, and fibrin degradation products on transendothelial migration of leukocytes, *Thromb. Res.* (2018), <http://dx.doi.org/10.1016/j.thromres.2017.11.007>.
- [6] S. Yakovlev, I. Mikhailenko, C. Cao, L. Zhang, D.K. Strickland, L. Medved, Identification of VLDLR as a novel endothelial cell receptor for fibrin that modulates fibrin-dependent transendothelial migration of leukocytes, *Blood* 119 (2012) 637–644.
- [7] J.W. Weisel, R.I. Litvinov, Fibrin formation, structure and properties, in: D.A.D. Parry, J. Squire (Eds.), *Subcellular Biochemistry*, Vol. 82 Springer, 2017, pp. 405–456.
- [8] M.J. Flick, X. Du, D.P. Witte, M. Jirousková, D.A. Soloviev, S.J. Busuttill, E.F. Plow, J.L. Degen, Leukocyte engagement of fibrin(ogen) via the integrin receptor  $\alpha \text{M}\beta 2/\text{Mac}-1$  is critical for host inflammatory response in vivo, *J. Clin. Invest.* 113 (2004) 1596–1606.
- [9] M.J. Flick, X. Du, J.M. Prasad, H. Raghu, J.S. Palumbo, E. Smeds, M. Höök, J.L. Degen, Genetic elimination of the binding motif on fibrinogen for the *S. aureus* virulence factor ClfA improves host survival in septicemia, *Blood* 121 (2013) 1783–1794.
- [10] J.M. Prasad, O.V. Gorkun, H. Raghu, et al., Mice expressing a mutant form of fibrinogen that cannot support fibrin formation exhibit compromised antimicrobial host defense, *Blood* 126 (2015) 2047–2058.
- [11] R.I. Litvinov, J.W. Weisel, Not fibrin(ogen), but fibrinogen or fibrin, *Blood* 126 (2015) 1977–1978.
- [12] L.R. Languino, A. Duperray, K.J. Joganic, M. Fornaro, G.B. Thornton, D.C. Altieri, Regulation of leukocyte-endothelium interaction and leukocyte transendothelial migration by intercellular adhesion molecule 1-fibrinogen recognition, *Proc. Natl. Acad. Sci. U. S. A.* 92 (1995) 1505–1509.
- [13] D.C. Altieri, Regulation of leukocyte-endothelium interaction by fibrinogen, *Thromb. Haemost.* 82 (1999) 781–786.
- [14] P. Petzelbauer, P.A. Zacharowski, Y. Miyazaki, P. Friedl, G. Wickenhauser, F.J. Castellino, M. Groger, K. Wolff, K. Zacharowski, The fibrin-derived peptide B $\beta$ 15–42 protects the myocardium against ischemia-reperfusion injury, *Nat. Med.* 11 (2005) 298–304.
- [15] K. Zacharowski, P. Zacharowski, S. Reingruber, P. Petzelbauer, Fibrin(ogen) and its fragments in the pathophysiology and treatment of myocardial infarction, *J. Mol. Med.* 84 (2006) 469–477.
- [16] C.T. Emsen, Crosstalk between inflammation and thrombosis, *Maturitas* 47 (2004) 305–314.

- [17] R.I. Litvinov, D.H. Farrell, J.W. Weisel, J.S. Bennett, The platelet integrin  $\alpha\text{IIb}\beta 3$  differentially interacts with fibrin versus fibrinogen, *J. Biol. Chem.* 291 (2016) 7858–7867.
- [18] P. Höök, R.I. Litvinov, O.V. Kim, S. Xu, Z. Xu, J.S. Bennett, M.S. Alber, J.W. Weisel, Strong binding of platelet integrin  $\alpha\text{IIb}\beta 3$  to fibrin clots: potential target to destabilize thrombi, *Sci. Rep.* 7 (2017) 13001.
- [19] A.R. Burns, D.C. Walker, E.S. Brown, L.T. Thurmon, R.A. Bowden, C.R. Keese, S.I. Simon, M.L. Entman, C.W. Smith, Neutrophil transendothelial migration is independent of tight junctions and occurs preferentially at tricellular corners, *J. Immunol.* 159 (1997) 2893–2903.

Rustem I. Litvinov\*

*Department of Cell and Developmental Biology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA*

*Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russian Federation*

*E-mail address:* litvinov@pennmedicine.upenn.edu

---

\* Department of Cell and Developmental Biology, University of Pennsylvania Perelman School of Medicine, 421 Curie Blvd., BRB II/III, Room 1109, Philadelphia, PA 19104, USA.